Hedera (HBAR) is back on traders’ radars heading into the final week of 2025, after pushing into the top performers list among major cryptocurrencies.
At the time of publication, Hedera was trading at $0.1157, up 4.91% over the past 24 hours and 6.08% on the week, with a market cap of $4.95 billion and 24-hour volume at $107.09 million, according to cryptocurrency market data tracked by Finbold.
The timing of the move is notable. While broader crypto markets remain mixed, historical data shows that HBAR has averaged gains of roughly 38% in January, a pattern often attributed to post-holiday portfolio rebalancing and renewed risk appetite at the start of the year. Traders appear to be positioning ahead of that seasonal trend, even as year-end dynamics continue to influence price action.
At the same time, the final days of December are traditionally shaped by tax-loss harvesting, which can suppress prices as investors sell underperforming assets to offset capital gains. For HBAR, this creates a delicate setup. If the token can hold above the $0.115 support zone through December 27–30, it may signal that selling pressure linked to tax considerations is being absorbed, clearing the path for a potential January rebound.
AI Hedera price forecast
To assess near-term direction, Finbold examined its custom AI forecasting engine, which aggregates predictions from Claude Sonnet 4, Gemini 2.5 Flash, and GPT-4o. For the period ending December 31, 2025, the models produced an average projected price of $0.115, implying a modest -1.33% move from the current level of $0.116 at the time the forecast was generated.
However, the range of outcomes highlights elevated volatility risk. Claude Sonnet 4 delivered the most optimistic scenario, pointing to a potential +6.27% upside, while Gemini 2.5 Flash outlined a downside case of -6.63%. This divergence reflects a market caught between short-term tax-driven selling and anticipatory buying ahead of January’s historically strong performance.
Taken together, HBAR’s recent surge, its consistent January seasonality, and the current tax-loss harvesting window suggest that price action into early 2026 could be decisive.
